Eli Lilly, Novo Nordisk, and Merck: The Pharma Showdown

Ladies and gentlemen, step right up for the ultimate financial showdown! Eli Lilly is smashing it with a 48% revenue growth and a blockbuster drug, Retatrutide, ready to rock the stock market! Novo Nordisk is feeling the heat with a 50% price cut on Wegovy—talk about a comeback kid! And Merck? They’re on a wild ride, up 31% this year, but waiting for the big reveal. Who will rise to the top? Stay tuned!